Jennifer Hart joins Julius Clinical

Posted on January 22, 2018

We are pleased to announce that Jennifer Hart has joined our company as Executive Director Business Development North America. In her new role as Executive Director, Ms. Hart will oversee the North American Business Development efforts for Julius Clinical and Cohortias, a joint venture between Julius Clinical and Zumanis.

read more

Andrew Copestake joins Julius Clinical

Posted on May 05, 2017

Julius Clinical is proud to announce that Andrew Copestake has been appointed as our new Chief Business Development Officer starting immediately. He will be part of the Management team together with Messrs. Smink (CEO), Grobbee (CSO) and Van Dijk (COO).

read more

Julius Clinical Forms Alliance With Parexel

Posted on April 04, 2017

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

Utrecht, Netherlands, January 25, 2017 — Julius Clinical, a globally-operating Academic Research Organization (ARO), today announced it has entered into a non-exclusive alliance with PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation. The alliance provides biopharmaceutical companies an approach to aligning scientific and operational aspects of a clinical trial.

read more